Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 3b study titled ‘Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO).’ The study aims to evaluate the efficacy and safety of combining ixekizumab with tirzepatide to improve psoriasis and aid weight reduction in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
Intervention/Treatment: The study tests two interventions: ixekizumab alone and ixekizumab combined with tirzepatide. Both drugs are administered subcutaneously, with ixekizumab targeting psoriasis and tirzepatide aimed at weight reduction.
Study Design: This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment. Participants are allocated randomly to receive either ixekizumab alone or in combination with tirzepatide.
Study Timeline: The study began on September 30, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing progress.
Market Implications: This study could significantly impact Eli Lilly’s stock performance by potentially expanding the market for ixekizumab if the combination therapy proves successful. Positive results may enhance investor sentiment, especially in the competitive landscape of psoriasis treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.